Skip to main content

Amber L. Beitelshees, PharmD, MPH

Academic Title:


Primary Appointment:



HSFIII, 670 W. Baltimore St, Room 4172

Phone (Primary):

(410) 706-0118


(410) 706-4060

Education and Training

Amber Beitelshees received her PharmD degree from the University of Florida. She then completed a residency in Pharmacy Practice at the University of Illinois Medical Center at Chicago. Dr. Beitelshees went on to complete a postdoctoral fellowship in Cardiovascular Pharmacogenomics and Master of Public Health degree in epidemiology at the University of Florida. She has served on the faculty at Washington University in St. Louis School of Medicine and the University of Florida College of Pharmacy. Dr. Beitelshees is currently Associate Professor of Medicine in the Division of Endocrinology, Diabetes and Nutrition.


Using my background in clinical pharmacology and pharmacogenomics, my research is aimed at understanding interpatient variability in drug response. One approach that we utilize is to leverage understanding of interpatient variability (e.g. pharmacogenomics) in the occurrence of adverse effects to gain mechanistic insights into underlying disease biology. We are particularly interested in the treatment of cardiovascular disease and diabetes.  We also investigate approaches for the clinical implementation of pharmacogenetics into routine medical care.  My lab utilizes genetic epidemiology, clinical pharmacology, and functional genomics to address these questions.  In my clinical role I serve on the Pharmacogenetics Service and the Pharmacogenetics subcommittee of the P&T committee to implement pharmacogenetic tests into clinical practice.

Research/Clinical Keywords

pharmacogenetics, pharmacogenomics, diabetes, hypertension, cardiovascular disease

Highlighted Publications

  1. Taylor SI, Yazdi ZS, Beitelshees AL, Pharmacological treatment of hyperglycemia in type 2 diabetes. J Clin Invest 2021; Jan 19;131(2):e142243. PMID: 33463546.
  2. Beitelshees AL, Stevenson JM, El Rouby N, Dillon C, Empey PE, Fielstein EM, Johnson JA, Limdi NA, Ong HH, Franchi F, Angiolillo DJ, Peterson JF, Rosenman MB, Skaar TC, Tuteja S, Cavallari LH; IGNITE Pharmacogenetics WorkingGroup. Genet Med. 2020 Nov;22(11):1898-1902. PMID: 32678355.
  3. Gong Y, Wang Z, Beitelshees AL, McDonough CW, Langaee TY, Hall K, Schmidt SO, Curry RW, Gums JG, Bailey KR, Boerwinkle E, Chapman AB, Turner ST, Cooper-DeHoff RM, Johnson JA. Pharmacogenomic genome-wide meta-analysis of blood pressure response to beta-blockers in hypertensive African Americans. Hypertension 2016;67:556-63. PMID: 26729753

  4. Ellero-Simatos*, Beitelshees AL*, Lewis JP, Yerges-Armstrong, Georgiades A, Dane A, Harms AC, Strassburg K, Guled F, Hendriks MM, Horenstein RB, Shuldiner AR, Hankemeier T, Kaddurah-Daouk R. Oxylipid profile of low-dose aspirin exposure: a pharmacometabolomics study. J Am Heart Assoc 2015;Oct 26;4(10). PMID: 26504148. *contributed equally

  5. Del-Aguila JL, Beitelshees AL, Cooper-DeHoff RM, et al. Genome-wide association analyses suggest NELL1 influences adverse metabolic response to HCTZ in African- Americans. Pharmacogenomics J 2014;14:35-40; doi:10.1038/tpj.2013.3.  PMID: 23400010.

  6. Beitelshees AL, Veenstra DL. Evolving research and stakeholder perspectives on pharmacogenomics.  JAMA 2011;306(11):1252-3. PMID: 21934059.